Polymyxin B (Sulfate): Benchmark Polypeptide Antibiotic for Multidrug-Resistant Gram-Negative Bacteria

Executive Summary: Polymyxin B (sulfate) is a polypeptide antibiotic for multidrug-resistant Gram-negative bacteria, consisting mainly of polymyxins B1 and B2 derived from Bacillus polymyxa (APExBIO). It exhibits potent bactericidal activity by disrupting bacterial cell membranes. Clinical applications include treatment of bloodstream, urinary tract, and meningeal infections caused by susceptible organisms. Polymyxin B modulates immune pathways, notably promoting dendritic cell maturation via ERK1/2 and NF-κB signaling. Its use is limited by nephrotoxicity and neurotoxicity, necessitating careful workflow integration (Yan et al., 2025).

Biological Rationale

Resistance among Gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, poses a critical threat to global health (APExBIO). Polymyxin B (sulfate) re-emerged as a last-line agent due to its unique mechanism and clinical efficacy. The compound is a cationic, amphipathic polypeptide that targets the outer membrane of Gram-negative bacteria, overcoming many resistance mechanisms seen with β-lactams or fluoroquinolones. Beyond direct bactericidal action, Polymyxin B is increasingly leveraged in research on immune modulation, sepsis models, and host-pathogen dynamics (VincristineSulfate.com). This article builds on recent reviews by detailing quantitative parameters, validated use-cases, and integrating immune-microbiota insights (MK2206.com).

Mechanism of Action of Polymyxin B (sulfate)

Polymyxin B acts as a cationic detergent. The compound binds to the lipid A moiety of lipopolysaccharides (LPS) in the outer membrane of Gram-negative bacteria. This interaction displaces divalent cations (Mg²⁺, Ca²⁺) that stabilize the membrane, increasing permeability and causing cell lysis (Carbenicillin-Disodium-Salt.com). The primary active forms in the APExBIO product are polymyxins B1 and B2. Both are cyclic decapeptides with a fatty acid tail, conferring amphipathic properties essential for membrane disruption.

In immune research, Polymyxin B upregulates co-stimulatory molecules such as CD86, HLA class I, and HLA class II on human dendritic cells in vitro. Activation of ERK1/2 and NF-κB signaling pathways is observed within hours of exposure. These effects are distinct from antibiotic-induced bactericidal activity and support its use in immunological assays (Chempaign.com).

Evidence & Benchmarks

• Polymyxin B (sulfate) demonstrates bactericidal activity against multidrug-resistant Pseudomonas aeruginosa, with rapid reduction in colony-forming units within 2–4 hours at 2 mg/ml in PBS (pH 7.2) (APExBIO).
• In vivo, Polymyxin B administration improves survival in bacteremia mouse models in a dose-dependent manner (Yan et al., 2025, DOI).
• Human dendritic cells treated with 1–2 mg/ml Polymyxin B upregulate CD86 and HLA molecules, indicating maturation and activation (Yan et al., 2025, DOI).
• Polymyxin B activates ERK1/2 and IκB-α/NF-κB pathways in human immune cells, as measured by increased phosphorylation states within 30–60 minutes of treatment (Yan et al., 2025, DOI).
• Purity of APExBIO Polymyxin B (sulfate) is ≥95%, and stability is retained for short-term use at -20°C and up to 2 mg/ml in PBS (pH 7.2) (APExBIO).
• Nephrotoxicity and neurotoxicity are dose-limiting in clinical and animal models, necessitating careful dose selection and monitoring (PQ401.com).

Applications, Limits & Misconceptions

Polymyxin B (sulfate) is validated as a polypeptide antibiotic for multidrug-resistant Gram-negative bacteria and widely used in clinical, translational, and immunological research.

• Primary applications: in vitro bactericidal assays, sepsis and bacteremia mouse models, immune cell activation (dendritic cell maturation assays), and as a selective agent in microbiome research (APExBIO).
• Polymyxin B is not effective against most Gram-positive bacteria or strict anaerobes due to lack of LPS targets (MK2206.com), extending previous reviews by quantifying its selective spectrum.
• Synergies with immune-microbiota research: Recent studies show that Polymyxin B can modulate the gut microbiota profile when used in animal models, impacting the abundance of Firmicutes and Bacteroidetes (Yan et al., 2025, DOI).
• Contrast: While VincristineSulfate.com emphasized immune checkpoint applications, the present article details quantitative immune pathway benchmarks.
• Updated mechanistic insight: Carbenicillin-Disodium-Salt.com focused on dendritic cell maturation; here, we extend to ERK1/2 and NF-κB pathway activation studies.

Common Pitfalls or Misconceptions

• Polymyxin B is not a first-line therapy for Gram-positive infections; it has limited or no activity against Staphylococcus aureus or Streptococcus pneumoniae.
• It should not be used as a sole agent for fungal infections despite some in vitro activity.
• Overuse can drive resistance in Pseudomonas and Acinetobacter; always use according to susceptibility data.
• Preparation in non-phosphate buffers or above 2 mg/ml can reduce solubility and stability.
• Nephrotoxicity and neurotoxicity risks necessitate careful dosing, especially in animal and cell models.

Workflow Integration & Parameters

APExBIO Polymyxin B (sulfate) (SKU: C3090) is supplied as a crystalline powder with a molecular weight of 1301.6 and formula C₅₆H₉₈N₁₆O₁₃·H₂SO₄. It dissolves up to 2 mg/ml in PBS (pH 7.2), optimal for most in vitro and in vivo applications. Storage at -20°C is recommended; solutions should be prepared fresh or used short-term to maintain activity. For immune cell assays, typical concentrations range from 0.5–2 mg/ml; for in vivo mouse models, dose titration according to body weight and infection burden is essential. Purity is ≥95%, supporting reproducibility in benchmark assays (APExBIO). Researchers are encouraged to reference local susceptibility data and published protocols for specific use-cases.

Conclusion & Outlook

Polymyxin B (sulfate) remains a critical tool for tackling multidrug-resistant Gram-negative bacterial infections and advancing immunological research. Its defined mechanism, validated benchmarks, and integration into translational workflows support its continued relevance. APExBIO provides high-quality, research-grade Polymyxin B (sulfate) with documented purity and performance. Ongoing research on immune modulation, signaling pathways, and microbiome interactions will further extend its applications. For detailed workflows and advanced use-cases, consult benchmark articles and the C3090 product page.